Programs & Research
Our pipeline diversification offers opportunities to advance novel treatments across therapeutic areas and mechanisms of action
MM-120 | LSD D-tartrate
Lead Candidate with Evidence Across Multiple Therapeutic Areas
Extensive evidence of clinical benefit and mechanistic rationale in psychiatry, pain and substance use disorders
MM-110 | Zolunicant HCl
Novel Mechanism to Address a Critical Gap in OUD Treatment
Mechanism of action and target product profile complement standard-of-care and address a critical gap in available treatment landscape
MM-402 | R(-)-MDMA
Clinical Data Support Opportunity in ASD
Pilot clinical trial results of MDMA demonstrate acute and durable positive effects on social functioning in ASD population
1. Pitts 2018; Psychopharmacology; 235.
2. Curry 2018; Neuropharmacology; 128.
Translational preclinical data suggest that R(-)-MDMA may have:
- Strong prosocial effects
- Less stimulant activity compared to MDMA
- Superior safety and tolerability profile
- Potential to be administered in standard dosing regimen
Early R&D
External Collaborations Accelerate Discovery & Development
Leveraging key partnerships and collaborations to accelerate drug discovery and de-risk clinical development
